At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed May 27, 2026 at 09:05 ET
Myriad Genetics announced it will present data at ASCO 2026 showing its Precise MRD test achieved 97% baseline detection across multiple cancer types in the MONSTAR-SCREEN-3 study, with 16% of samples detected at ultrasensitive levels. The data supports the clinical utility of the test for recurrence monitoring, but this is a scientific conference presentation with no immediate revenue or regulatory catalyst.
- Precise MRD test achieved 97% baseline ctDNA detection in MONSTAR-SCREEN-3 pan-cancer analysis
- 16% of samples detected in the ultrasensitive range
- ctDNA-positive patients at 1-month post-surgery had significantly worse disease-free survival
- Data presented across six posters at ASCO 2026 covering gastric, ovarian, head/neck, sarcoma, and pan-cancer indications
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access